FDA Approves A180TM, A New BRD Treatment From Pfizer Animal Health
A180TM (danofloxacin mesylate), a new antimicrobial treatment for bovine respiratory disease (BRD) associated with Mannheimia (Pasteurella) haemolytica and Pasteurella multocida in beef cattle, has received FDA approval.
Developed by Pfizer specifically and exclusively for livestock use, A180 gives beef producers and veterinarians what theyve been looking for an effective solution to BRD treatment, with a unique four-day withdrawal period. A180 is administered as a concentrated low-volume subcutaneous injection (1.5 mL per 100 lbs. bodyweight) that is easy on cattle and offers convenience with less medical waste.